References
- Urba W J, Longo D L. Hodgkins disease. N Engl J Med 1992; 326: 678–687
- Canellos G P, Anderson J R, Propert K J, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478–1484
- Connors J M, Klimo P, Adams G, et al. Treatment of advanced Hodgkin's disease with chemotherapy - Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997; 15: 1638–1645
- Glick J H, Young M L, Harrington D, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the Intergroup trial. J Clin Oncol 1998; 16: 19–26
- Duggan D, Petroni J, Johnson J, et al. MOPP/ABV versus ABVD for advanced Hodgkin's disease - a preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC) [Abstract]. Proc Am Soc Clin Oncol 1997; 16: 12a
- Hasenclever D, Diehl V, International Prognostic Factors Project on Advanced Hodgkin's Disease. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506–1514
- Carde P, Mackintosh F R, Rosenberg S A. A dose and time analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1983; 1: 146–156
- Longo D L, Young R C, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295–1306
- Van Rijswijk R EN, Haanen C, Dekker A W, et al. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol 1989; 7: 1776–1782
- Pettengell R, Guyrney H, Radford J A, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430–1436
- Bonadonna G, Santoro A. ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 1992; 9: 21–35
- Rueda A, Alba E, Ribelles N, et al. Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study. J Clin Oncol 1997; 15: 1118–1122
- Lister T A, Crowther D, Sutcliffe S B, et al. Report of a Committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630–1636
- Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252–259
- Miller A B, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
- American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471–2508
- American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996; 14: 1957–1960
- Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 Twin Randomized Trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11: 2258–2272
- Silvestri F, Fanin R, Velisig M, et al. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease. Tumori 1994; 80: 453–458
- Diehl V, Franklin J, Hasenclever D, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998; 16: 3810–3821
- Diehl V, Sieber M, Franklin J, et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial [Abstract]. Ann Oncol 1999; 10(Suppl 3)22